menu search

TALS / Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
Shares of cell therapy concern Talaris Therapeutics crashed nearly 70% after GvHD outcomes in three Phase 3 trial kidney transplant patients were revealed at the end of June 2022. Even though its stock has essentially doubled off its update-induced low, it still trades at a discount to cash. Read More
Posted: Aug 29 2022, 07:59
Author Name: Seeking Alpha
Views: 112541

TALS News  

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

By Seeking Alpha
August 29, 2022

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Shares of cell therapy concern Talaris Therapeutics crashed nearly 70% after GvHD outcomes in three Phase 3 trial kidney transplant patients were reve more_horizontal

Talaris Therapeutics to Participate at Two Upcoming Investor Conferences

By GlobeNewsWire
March 22, 2022

Talaris Therapeutics to Participate at Two Upcoming Investor Conferences

BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company d more_horizontal


Search within

Pages Search Results: